/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Indaptus Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$2.16 0.08(8%) INDP at 04 Dec 2025 04:35 PM Biotechnology
Lowest Today 2.03
Highest Today 2.07
Today’s Open 2.03
Prev. Close 2
52 Week High 29.68
52 Week Low 1.65
Day’s Range: Low 2.03 High 2.07
52-Week Range: Low 1.65 High 29.68
1 day return -
1 Week return -5.02
1 month return -28.52
3 month return -54.58
6 month return +511.76
1 year return +100.0
3 year return +10.63
5 year return -85.33
10 year return -

Institutional Holdings

Fidelity Extended Market Index 0.21

Vanguard Institutional Extnd Mkt Idx Tr 0.06

Fidelity Series Total Market Index 0.05

Fidelity Total Market Index 0.04

NT Ext Equity Mkt Idx Fd - NL 0.02

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.02

SBI Securities Co Ltd 0.01

Spartan Total Market Index Pool G 0.01

Northern Trust Extended Eq Market Idx 0.01

NT Ext Equity Mkt Idx Fd - L 0.01

Tower Research Capital LLC 0.01

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

Bank of America Corp 0.00

NT Ext Eq Mkt Indx Fd DC Lend T3 0.00

Spartan Extended Market Index Pool F 0.00

FMR Inc 0.00

Wells Fargo & Co 0.00

Bangor Savings Bank 0.00

Geode Capital Management, LLC 0.00

Group One Trading, LP 0.00

Investment House LLC 0.00

JPMorgan Chase & Co 0.00

Morgan Stanley - Brokerage Accounts 0.00

Renaissance Technologies Corp 0.00

State Street Corp 0.00

Strategy Asset Managers LLC 0.00

Susquehanna International Group, LLP 0.00

TWO SIGMA SECURITIES, LLC 0.00

UBS Group AG 0.00

Vanguard Group Inc 0.00

Virtu Financial LLC 0.00

Vivaldi Capital Management, LLC 0.00

Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 3.50 M

PB Ratio 0.8479

PE Ratio 0.0

Enterprise Value -1.91 M

Total Assets 7.34 M

Volume 10478

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:null 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-15076468 -15.1M, FY22:-13734690 -13.7M, FY21:-7693664 -7.7M, FY20:-3569037 -3.6M, FY19:null 0.0M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-2975117 -3.0M, Q2/2025:-5228919 -5.2M, Q1/2025:-4532430 -4.5M, Q3/2024:-3069036 -3.1M, Q2/2024:-4015267 -4.0M

Fund house & investment objective

Company Information Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Organisation Biotechnology

Employees 7

Industry Biotechnology

CEO Mr. Jeffrey A. Meckler J.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow